Abstract
Although a vaccine against SARS-CoV-2 Omicron-XBB.1.5 variant is available worldwide and recent infection is protective, the lack of recorded infection data highlights the need to assess variant-specific antibody neutralization levels. We analyzed IgG levels against receptor-binding domain-specific SARS-CoV-2 ancestral strain as a correlate for high neutralizing titers against XBB variants.
Keywords:
COVID-19; IgG; Israel; SARS-CoV-2; XBB variant; antibodies; neutralizing antibodies; respiratory infections; vaccine-preventable diseases; vaccines; viruses.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antibodies, Neutralizing* / blood
-
Antibodies, Neutralizing* / immunology
-
Antibodies, Viral* / blood
-
Antibodies, Viral* / immunology
-
COVID-19 Vaccines / immunology
-
COVID-19* / epidemiology
-
COVID-19* / immunology
-
COVID-19* / prevention & control
-
Female
-
Humans
-
Immunoglobulin G* / blood
-
Immunoglobulin G* / immunology
-
Israel / epidemiology
-
Male
-
Middle Aged
-
Neutralization Tests
-
SARS-CoV-2* / genetics
-
SARS-CoV-2* / immunology
-
Spike Glycoprotein, Coronavirus / genetics
-
Spike Glycoprotein, Coronavirus / immunology
Substances
-
Immunoglobulin G
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Spike Glycoprotein, Coronavirus
-
COVID-19 Vaccines